Day: January 4, 2022

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) — Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced its strategic priorities and upcoming catalysts for 2022. “In 2021 we announced positive Phase 2 clinical data for our first SINTAX-based medicine EDP1815 in psoriasis, demonstrating that EDP1815 is a potential medicine that can be delivered orally to drive systemic therapeutic effects with safety and tolerability comparable to placebo. These data support our vision to transform healthcare with a new type of medicine that can be used globally to treat all stages of inflammatory disease,” said Simba Gill, Ph.D., Chief Executive Officer of Evelo. “In 2022, we will continue to advance our...

NEW YORK and VIENNA, Austria, Jan. 04, 2022 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the Company will present at the virtual H.C. Wainwright BioConnect Conference, January 10 – 13, 2022.   The presentation will be available beginning at 7:00 AM EST on Monday, January 10. The webcast of the presentation will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. An archived replay will be accessible for 30 days following the event. About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies that mobilize and amplify targeted T cells to address...

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present a Company overview at the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. The pre-recorded presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. ET by visiting ‘Events’ in the Investor Relations section of the Company’s website at www.akaritx.com. A webcast replay will be accessible for 90 days following the event. About Akari Therapeutics Akari is a biopharmaceutical company focused on developing inhibitors...

NEW YORK, Jan. 04, 2022 (GLOBE NEWSWIRE) — Prospect Capital Corporation (NASDAQ: PSEC) (“Prospect”, “our”, or “we”) announced today that Prospect’s preferred stock offerings (collectively, the “Preferred Stock”) have exceeded $450 million in aggregate liquidation preference issuances since the initial closing in the quarter ending December 31, 2020. “Prospect’s preferred stock offers investors recurring cash income with a stable stated value, ongoing liquidity, management alignment, leverage caps, and nearly $4 billion of junior common equity credit support,” said Grier Eliasek, President of Prospect. “Each of the institutional, registered investment advisor, wirehouse, and independent private wealth investor channels have invested in Prospect’s preferred stock.” Preferred Capital Securities LLC (“PCS”) is a securities...

DODGEVILLE, Wis., Jan. 04, 2022 (GLOBE NEWSWIRE) — Lands’ End, Inc. (NASDAQ: LE) today announced that the Company is scheduled to participate in a fireside chat at the 24th Annual ICR Conference, held virtually, on Tuesday, January 11, 2022 at 9:30 AM Eastern Time. Chief Executive Officer, Jerome Griffith, and President and Chief Financial Officer, Jim Gooch, will participate in the fireside chat. The fireside chat presentation will be webcast live over the internet and can be accessed at http://investors.landsend.com. An online archive will be available for a period of 90 days following the presentation. In addition, the Company plans to post an investor presentation to the investor relations section of its website prior to the webcast. About Lands’ End, Inc. Lands’ End, Inc. (NASDAQ:LE) is a leading uni-channel...

GUANGZHOU, China, Jan. 04, 2022 (GLOBE NEWSWIRE) — LIZHI INC. (“LIZHI” or the “Company”) (NASDAQ: LIZI), an audio-based social and entertainment platform, concludes a remarkable year of growth that saw the Company hit several major milestones throughout 2021, from expanding its global presence to enhancing its product portfolio and technology. With the development of LIZHI’s global audio ecosystem, LIZHI is dedicated to satisfying user demands through diversified social and interactive entertainment products. While LIZHI was originally known for its flagship LIZHI App, the Company has since diversified its products to include global hit social app TIYA and the vertical podcast platform LIZHI Podcast App. The products are powered by the Company’s proprietary real-time communication (RTC) technology – dubbed...

Klaipėda District Prosecutor’s Office of Klaipėda Regional Prosecutor’s Office has announced that it has completed the pre-trial investigation in environmental case regarding wastewater management by Grigeo Klaipėda AB, a subsidiary of Grigeo AB, when partially treated wastewater of Grigeo Klaipėda AB would be discharged in the collector of Klaipėdos Vanduo AB to finally end up in the Curonian Lagoon and has referred the case to the court. The court proceedings have not yet begun and is likely to begin in a few months. Grigeo Klaipėda AB has assumed it’s legal liability for wrongful acts and has repeatedly stated that it intends to remedy all environmental damage, if and when the existence and amount of such damage is established in accordance with the European Union directives and national legislation implementing them. In the opinion...

MELBOURNE, Australia, Jan. 04, 2022 (GLOBE NEWSWIRE) — Opthea Limited (ASX:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced today that Dr Megan Baldwin, the Company’s Chief Executive Officer, will participate in the H.C. Wainwright BIOCONNECT Conference, being held virtually from January 10-13, 2022. The pre-recorded presentation will be available beginning Monday, January 10, at 7:00 am ET (11:00 pm AET), and may be accessed on the Investors page of the Opthea website at https://www.opthea.com/presentations/. About Opthea Limited Opthea (ASX:OPT; Nasdaq:OPT) is a biopharmaceutical company developing novel therapies to address the unmet need in the treatment of highly prevalent and progressive retinal diseases, including wet age-related...